NASDAQ:SNTS

Santarus (SNTS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$16,995.00
$16,995.00
52-Week Range
N/A
Volume
54,432 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SNTS stock logo

About Santarus Stock (NASDAQ:SNTS)

Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company’s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company’s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

SNTS Stock News Headlines

Societe Nationale des Telecommunications SONATEL SNTS
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Biotech Stock Mailbag: Cardium Therapeutics
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Saints report: CSS earn MIAC men’s hockey sweep of Cobbers
Saints report: CSS men victorious at Augsburg
Santarus Stock Hits New 52-Week High (SNTS)
Cramer's 'Mad Money' Recap: The Knot Worth Tying
5 Stocks Insiders are Buying This Week
See More Headlines
Receive SNTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santarus and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SNTS
CUSIP
80281730
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

SNTS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Santarus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Santarus investors own include Baidu (BIDU), Home Depot (HD), Pharmacyclics (PCYC), Yelp (YELP), ACADIA Pharmaceuticals (Acad), Altaba (AABA), Allergan (AGN), Alexion Pharmaceuticals (ALXN) and Cree (CREE).

This page (NASDAQ:SNTS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners